Tofacitinib · TOFACITINIB CITRATE 5 mg/1 · Tablet, Film Coated · Oral · Macleods Pharmaceuticals Limited
NDC 33342-0541-09 · 60 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
12 companies supply this market — deep enough that no single failure threatens the supply. The brand (Xeljanz) runs $88.80 per unit — 155× more. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 00069-1001-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Apotex Corp. | TOFACITINIB 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Apotex Corp. | TOFACITINIB 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | TOFACITINIB CITRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | TOFACITINIB CITRATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | TOFACITINIB CITRATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | TOFACITINIB CITRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Micro Labs Limited | TOFACITINIB CITRATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Micro Labs Limited | TOFACITINIB CITRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | TOFACITINIB CITRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | TOFACITINIB CITRATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Pfizer Laboratories Div Pfizer Inc | TOFACITINIB CITRATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Pfizer Laboratories Div Pfizer Inc | TOFACITINIB CITRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Somerset Therapeutics, LLC | TOFACITINIB CITRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Somerset Therapeutics, LLC | TOFACITINIB CITRATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| U.S. Pharmaceuticals | TOFACITINIB CITRATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| U.S. Pharmaceuticals | TOFACITINIB CITRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | TOFACITINIB CITRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | TOFACITINIB CITRATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | TOFACITINIB CITRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | TOFACITINIB CITRATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | TOFACITINIB CITRATE 5 mg/1 | Jul 25, 2026 | Aug 29, 2026 |
| AvKARE | TOFACITINIB CITRATE 10 mg/1 | Jul 25, 2026 | Aug 29, 2026 |
| Golden State Medical Supply, Inc. | TOFACITINIB 5 mg/1 | Aug 15, 2026 | Aug 29, 2026 |
| Golden State Medical Supply, Inc. | TOFACITINIB 10 mg/1 | Aug 15, 2026 | Aug 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Tofacitinib — NDC 33342-0541-09," retrieved September 3, 2026, https://drugdashboards.com/drug/33342054109.
Free to cite with attribution — see how the data is put together.